United Therapeutics | UTHR - Gross Profit On Sales

Stock Price
478.93
Daily Change
-3.66 -0.76%
Monthly
-4.73%
Yearly
35.39%
Q1 Forecast
455.03

United Therapeutics reported $602.1M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Amarin USD 22.21M 28.15M Sep/2025
Ardelyx USD 106.35M 23.51M Sep/2025
Baxter International USD 950M 194M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.68B 358.6M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
J&J USD 16.6B 118M Dec/2025
Moderna USD 809M 791M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025